STAT3 and non-small cell lung carcinoma: To investigate whether the inhibition of MKNK, STAT3, and MCL1 could play a role in the effects of sorafenib in NSCLC cells, we tested specific inhibitors of these three factors (Supplementary Fig. 4F, G).